Mark Erlander, Cardiff Oncology CEO
March 1, 2024 07:12 AM ESTUpdated 11:07 AM
R&D

Cardiff teas­es on­va­nsert­ib ef­fi­ca­cy in col­orec­tal can­cer ahead of first-line read­out

Ayisha Sharma

News Reporter

Cardiff On­col­o­gy’s PLK1 in­hibitor showed hints of ef­fi­ca­cy in a shelved Phase II test in sec­ond-line col­orec­tal can­cer, boost­ing Cardiff’s share price ahead of an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times